StockMarketWire.com - Cancer therapies and diagnostics group Avacta entered into a global distribution agreement with ABCAM to sell the company'sSARS-CoV-2 research Affimer reagents.

Under the worldwide, non-exclusive distribution agreement, ABCAM would enable the global research community to access Avacta's SARS-CoV-2 spike protein Affimer research reagents through its on-line catalogue.








At 9:26am: [LON:AVCT] Avacta Group PLC share price was 0p at 111.5p



Story provided by StockMarketWire.com